BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints

-0.72%

-0.51%

-1.07%

-1.69%

Incyte Corporation INCY	95.41	-0.72%
Dow Jones Industrial Average DJI	48458.05	-0.51%
S&P 500 index SPX	6827.41	-1.07%
NASDAQ IXIC	23195.17	-1.69%

March 8 (Reuters) - Incyte Corp INCY.O:

INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLITINIB CREAM 1.5% (OPZELURA®) IN PATIENTS WITH PRURIGO NODULARIS (PN) AT 2025 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING
INCYTE CORP - PHASE 3 TRUE-PN1 STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS
INCYTE - TOPLINE DATA FROM SEPARATE PHASE 3 STUDY, TRUE-PN2, SHOWED THAT PRIMARY ENDPOINT DID NOT REACH STATISTICAL SIGNIFICANCE

Source text: ID:nBw6wcHHDa

Further company coverage: INCY.O

((Reuters.Briefs@thomsonreuters.com;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.